Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...

PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Regulatory News: Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces it has entered into a strategic alliance ...

Rapid diagnosis of TB is vital in areas such as sub-Saharan Africa and Southeast Asia due to the close connection between HIV and TB. Sputum microscopy, which often delivers poor sensitivity in ...

Q3 2025 Management View CEO Rainer Blair emphasized strong third quarter results, driven by "DBS-driven execution paired with ...

(RTTNews) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic ...

The all-cash deal will expand Danaher's already hefty life sciences division. D.C.-based Danaher Corp. (NYSE: DHR) is buying California molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) for ...

Cepheid said it will partner with MedImmune and a European public/private partnership that promotes anti-infective drug development to develop rapid diagnostic tests in respiratory secretions of ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

For much of last year, the coronavirus crept, undetected, across eastern Democratic Republic of Congo. Test samples had to be sent more than 1,500 kilometres from remote hospitals to the capital ...